A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies
NCT02730481
Completed
This is a multicenter, open-label, safety study. Eligible subjects will be adults with advanced malignancies. The study includes a pretreatment and treatment phase. The pretreatment phase consists of screening and baseline periods. The treatment phase consists of 4-week treatment periods and a follow-up period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2021
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +2 locations
Conditions: Solid Tumor
Register for Updates
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel
NCT02073487
Completed
This is a randomized, open label Phase II neoadjuvant study comparing the efficacy and safety of trastuzumab emtansine (T-DM1) plus lapatinib (L)followed by abraxane (A) versus trastuzumab plus pertuzumab followed by paclitaxel in patients with HER2-overexpressing breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/27/2021
Locations: Houston Methodist Hospital, Houston, Texas +2 locations
Conditions: Breast Cancer
Register for Updates
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT02366143
Completed
This randomized, open-label study evaluated the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 \[PD-L1\] antibody) in combination with carboplatin+paclitaxel with or without bevacizumab compared with treatment with carboplatin+paclitaxel+bevacizumab in chemotherapy-naïve participants with Stage IV non-squamous NSCLC. Participants were randomized in a 1:1:1 ratio to Arm A (Atezolizumab+Carboplatin+Paclitaxel), Arm B (Atezolizumab+Carboplatin+Paclitaxel+Bevacizum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2021
Locations: Ironwood Cancer & Research Centers, Chandler, Arizona +239 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
NCT01593020
Completed
The goal of this clinical research study is to learn if and how well eribulin, given in combination with standard chemotherapy, can treat early-stage breast cancer compared to paclitaxel given in combination with standard chemotherapy. In this study, the standard chemotherapy being given is either 5-fluorouracil, epirubicin, and cyclophosphamide (called FEC) or 5-fluorouracil, doxorubicin, and cyclophosphamide (called FAC). Eribulin is a changed version of the structure of a natural substance f... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/26/2021
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT00004202
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as RSR13 may make tumor cells more sensitive to radiation therapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, radiation therapy, and RSR13 in treating patients who have stage III non-small cell lung cancer that cannot be removed by surgery.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/20/2021
Locations: Arizona Cancer Center, Tucson, Arizona +15 locations
Conditions: Lung Cancer
Register for Updates
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
NCT01847001
Completed
This study is being conducted in patients with newly diagnosed breast cancer that will be undergoing chemotherapy prior to surgery - neoadjuvant chemotherapy. The study involves treatment with standard chemotherapy and a commonly used, FDA-approved, blood pressure drug called propranolol (Inderal). The purposes of this study are to: 1. Determine the effect of propranolol plus chemotherapy on breast cancer cells as well as the growth of blood vessels surrounding breast cancer cells. 2. Determine... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/19/2021
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Locally Advanced Malignant Neoplasm, Breast Cancer
Register for Updates
Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer
NCT03872505
Withdrawn
This phase II randomized trial is for patients with clinical stage II-III, ER and PR \<10%, HER2-negative invasive breast carcinoma (triple negative breast cancer) for whom adjuvant RT is planned and pre-operative RT is deemed feasible by the treating radiation oncologist. Subjects will be randomized into arm A or B and treatment will last for 16 weeks. Both groups will receive Durvalumab 750mg IV Q2 weeks x 2 then a biopsy prior to durvalumab 1500mg IV Q4 weeks x 3 with paclitaxel and carboplat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2021
Locations: Cedars Sinai Medical Center, Los Angeles, California
Conditions: Breast Cancer, Triple Negative Breast Cancer
Register for Updates
A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
NCT02132949
Completed
This multicenter, non-randomized, open-label, phase 2 study is designed to evaluate the safety and efficacy of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and anthracycline-based chemotherapy as neoadjuvant treatment in participants with HER2-positive locally advanced, inflammatory, or early-stage breast cancer. Each investigator will choose a treatment regimen (A or B) for all of their participants to follow. Treatment regimen A (for Cohort A) will include dose-dense doxoru... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2021
Locations: University of South Alabama; Mitchell Cancer Institute, Mobile, Alabama +79 locations
Conditions: Breast Cancer
Register for Updates
Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer
NCT02138383
Completed
The main purpose of this study is to find out the dose of enzalutamide that can be safely given with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer. Researchers also want to find out the side effects of these drugs when given together. This study will help in finding out the effect on tumor of the combination of enzalutamide, gemcitabine and nab-paclitaxel. In the first part of the study, different doses of enzalutamide will be tested. In the second part of the study,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2021
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Pancreatic Cancer
Register for Updates
Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344
NCT00897026
Completed
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors plan the best treatment. PURPOSE: This research study is looking at tissue samples from women who underwent chemotherapy for lymph node-positive stage II or stage IIIA breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/16/2021
Locations: Washington University, Saint Louis, Missouri
Conditions: Breast Cancer
Register for Updates
Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer
NCT03394885
Completed
The main purpose of this study is to validate a safe dose of atezolizumab with dose-dense paclitaxel and carboplatin when utilized with neoadjuvant chemotherapy and interval cytoreductive surgery followed by maintenance atezolizumab in women with advanced ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/10/2021
Locations: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland +2 locations
Conditions: Ovarian Cancer, Ovarian Neoplasms
Register for Updates
Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer
NCT03316599
Completed
To identify the maximally tolerated dose of ficlatuzumab when combined with nab-paclitaxel and gemcitabine in patients with previously untreated pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2021
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Pancreatic Cancer
Register for Updates